ClinicalTrials.gg
RecruitingNCT05783817MDMA-CBT4OCDUpdated Mar 5, 2026

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

A Phase 2 interventional study of 3,4-Methyl enedioxy methamphetamine and Methamphetamine in Obsessive-Compulsive Disorder, sponsored by Carolyn Rodriguez. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Carolyn Rodriguez · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.

Planned enrollment
122nd of 246
40 · median 40
Started
2025
with 16 others
Phase 2
46 of 299
6 open now
Primary completion
2026-12
later than 15 of 76 live
Registered
251st of 299
by date

Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 122nd largest by planned enrollment of the 246 interventional ones that give a count, is one of 17 that started in 2025, is one of 46 in phase 2, reaches primary completion later than 15 of the 76 other live ones, and was the 251st registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Obsessive-Compulsive Disorder with a site in United States, or all of them as a file.
02

Study summary

The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).

Read the detailed description

Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. The proposed projects tests whether 3,4-Methylenedioxymethamphetamine (MDMA) reduces OCD symptoms.

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • OCD
  • MDMA
  • OCD CBT
  • Cognitive Behavioral Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old
  2. Fluent in speaking and reading the predominantly used or recognized language of the study site
  3. Able to swallow pills
  4. Meet the criteria for OCD diagnosis
  5. YBOCS total score of at least 16
  6. Not on psychotropic medications 1 month prior to study enrollment
  7. Able to tolerate a treatment-free period
  8. Able to tolerate study procedures
  9. Failed at least 1 prior trial of standard OCD treatment
  10. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication dosing, therapy, and study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing, or able to become pregnant and are not practicing an effective means of
  2. Weigh less than 48 kilograms (kgs)
  3. Any current problem which, in the opinion of the investigator or study physician, might interfere with participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    MDMA-assisted cognitive behavioral therapy

    Administration of 80mg MDMA HCl (with a supplemental dose offered 1.5 to 2 hours later of 40 mg MDMA HCl) in combination with cognitive behavioral therapy (CBT).

    Drug: 3,4-Methyl enedioxy methamphetamine · Behavioral: Cognitive Behavioral Therapy (CBT)

  • Active comparator
    Methamphetamine-assisted cognitive behavioral therapy

    Administration of 10mg methamphetamine (with a supplemental dose offered 1.5 to 2 hours later of 5 mg methamphetamine) in combination with cognitive behavioral therapy (CBT).

    Drug: Methamphetamine · Behavioral: Cognitive Behavioral Therapy (CBT)

Interventions

  • DrugN-Methyl-3,4-methylenedioxyamphetamineStudies of N-Methyl-3,4-methylenedioxyamphetamineN-Methyl-3,4-methylenedioxyamphetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.

    Also known as: MDMA

  • Methamphetamine is a stimulant that affects the central nervous system. This is used as a control in the study.

    Also known as: MA

  • BehavioralCognitive Behavioral Therapy (CBT)

    Cognitive Behavioral Therapy with exposure and response prevention performed by therapist team.

06

What researchers measure

Primary outcomes

  1. Chnage in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

    Change in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.

    Time frame: Baseline (Visit 1) to End of Intervention (Visit 13), up to 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 Jun;27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. PubMed 33972795 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
Sep 10, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05783817
Lead sponsor
Carolyn Rodriguez
Responsible party
Carolyn Rodriguez (Professor, Stanford University) — Sponsor-investigator
First posted
Mar 24, 2023
Start date
Sep 10, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Alessa Gaeta, MS
Contact
ocdresearch@stanford.edu
650-723-4095
Carolyn Rodriguez, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion